Astrazeneca's (AZN) naloxegol product for treating opioid-induced constipation (OIC)...
Astrazeneca's (AZN) naloxegol product for treating opioid-induced constipation (OIC) performed well in two Phase III trials and one safety extension study. The trials also brought on no imbalances in serious adverse events. Astrazeneca acquired the worldwide licence for naloxegol from its developer, Nektar Therapeutics (NKTR -0.1%), in 2009. (PR)
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Nasdaq.com (Feb 17, 2015)
at Benzinga.com (Feb 5, 2015)
at CNBC.com (Feb 5, 2015)
at MarketWatch.com (Jan 14, 2015)
at CNBC.com (Jan 14, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs